期刊
VACCINE
卷 29, 期 47, 页码 8501-8505出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2011.09.012
关键词
Cancer vaccines; Phase 2 trials; Phase 3 trials; Need for biomarkers; Patient selection; Inflammation
资金
- Cancer Vaccine Institute
Immunotherapy is showing promise for the treatment of a range of tumours including prostate cancer, melanoma and non small-cell lung cancer. Phase II trial data has been extremely encouraging with regards both clinical outcome and the investigation of the underlying immunological mode-of-action. However, despite the positive phase II data there remains a high failure rate in late stage clinical trials which, in many cases can be ascribed to inappropriate trial design, poor patient selection and inconsistency in patient management. The potential impact of standard cancer treatments and other factors which may vary within patient populations is discussed. A perspective is provided on the failure of late-stage clinical trials across a range of platforms focusing particularly on melanoma and prostate cancer. (C) 2011 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据